Aytu BioPharma, Inc. reported earnings results for the fourth quarter ended June 30, 2023. For the fourth quarter, the company reported net loss was USD 2.46 million compared to USD 16.09 million a year ago. Basic loss per share from continuing operations was USD 0.59 compared to USD 8.95 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.88 USD | -3.68% | +1.05% | +1.41% |
05-15 | Transcript : Aytu BioPharma, Inc., Q3 2024 Earnings Call, May 15, 2024 | |
05-15 | Aytu BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.41% | 17.86M | |
+54.61% | 815B | |
+44.25% | 654B | |
-6.33% | 354B | |
+20.62% | 337B | |
+10.44% | 302B | |
+18.45% | 247B | |
+2.09% | 229B | |
+13.03% | 219B | |
+8.61% | 171B |
- Stock Market
- Equities
- AYTU Stock
- News Aytu BioPharma, Inc.
- Aytu BioPharma, Inc. Reports Earnings Results for the Fourth Quarter Ended June 30, 2023